Croda celebrates opening of expanded UK facility, bolstering global Super Refined™ capabilities

PRESS RELEASE

12 May 2025: Croda International Plc (“Croda”), the company that uses smart science to create high-performance ingredients and pharmaceutical excipients that improve lives, celebrated the opening of its newly expanded Super Refined™ manufacturing facility in Leek, Staffordshire, UK, with a ribbon-cutting ceremony.

The opening of this expanded facility marks a major step forward and coincides with the recent launch of Super Refined™ Poloxamer 188, a highly purified shear protectant designed for critical applications in cell culture and biopharmaceutical formulations. Attended by industry leaders and site representatives, the opening demonstrated Croda Pharma’s continued evolution and leadership in advancing biologics delivery.

This enhanced capability complements Croda’s established global Super Refined™ manufacturing footprint across Europe, the North America, and Asia, strengthening its ability to supply its broad portfolio of these high-purity excipients to customers worldwide.

Thomas Riermeier, newly appointed President of Life Sciences, who cut the ribbon at the event and joined the site team in celebrating the achievement, commented:

"Congratulations to the entire team for the safe and timely execution of this project. With our Super Refined™ Poloxamer 188, our customers will benefit from enhanced performance in their cell culture media used in biopharmaceutical manufacturing. We’ve invested in an exciting new technology and remain committed to innovating together with our customers and partners.

Katie Dec, Business Head for Croda’s small molecule and protein delivery platform, added:

"I’m excited to see this facility come online and actively support our innovation efforts in bioprocessing and formulation. It reflects our commitment to enabling both upstream and downstream bioprocessing, with Super Refined™ Poloxamer 188 and is a demonstration of how we deliver consistent, safe, and efficient solutions for biologic drug production."

With this expansion, Croda Pharma continues to drive innovation in excipient science, reinforcing its position as a trusted partner in delivering high-purity solutions that support the evolving needs of the biopharmaceutical industry.